Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 5:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 216 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Exposure Therapy + Placebo Clear all
Recruiting Phase 2 Interventional Accepts healthy volunteers

Facilitation of Extinction Retention and Reconsolidation Blockade by IV Allopregnanolone in PTSD.

NCT07079761
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Experiment 1. Three-day aversive conditioning, extinction, and extinction retention testing paradigm, Allopregnanolone (Allo) with 6% USP Dexolve (sulfobutyl ether-beta-cyclodextrin sodium salt) in 0.9% saline for IV infusion will be provided by the University of California, Davis, GMP manufacturer., Matching IV Placebo, Experiment 2. Three-day aversive conditioning, reconsolidation blockade, and testing paradigm
Behavioral · Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 7, 2026, 5:31 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

NCT01892722
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Interferon beta-1a, Fingolimod, Placebo capsule, Placebo i.m. injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
10 Years to 17 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 7, 2026, 5:31 AM EDT
Terminated Phase 2 Interventional

Cognitive REmediation After Trauma Exposure Trial = CREATE Trial

NCT01416948
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Traumatic Brain Injury
Interventions
Methylphenidate Hydrochloride 20 mg, Placebo Capsule, Galantamine 12 mg
Drug
Lead sponsor
INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
7
States / cities
San Diego, California • Boston, Massachusetts • Manchester, New Hampshire + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2013 · Synced Oct 7, 2026, 5:31 AM EDT
Completed Phase 2 Interventional

BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy

NCT01873404
View directory record Official record
Conditions
Painful Lumbar Radiculopathy, Sciatica, Radiculopathy
Interventions
BG00010, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
25
States / cities
Phoenix, Arizona • Fresno, California • Lomita, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2015 · Synced Oct 7, 2026, 5:31 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Alpha-Lipoic Acid in Preventing Hearing Loss in Cancer Patients Undergoing Treatment With Cisplatin

NCT00477607
View directory record Official record
Conditions
Ototoxicity, Unspecified Adult Solid Tumor
Interventions
alpha-lipoic acid, Audiology, laboratory biomarker analysis, Placebo
Drug · Behavioral · Biological
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 7, 2014 · Synced Oct 7, 2026, 5:31 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure

NCT07562087
View directory record Official record
Conditions
Lyme Disease
Interventions
TP-05 (lotilaner) Low Dose, TP-05 (lotilaner) High Dose, Placebo
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
722 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
19
States / cities
Pikesville, Maryland • Brookline, Massachusetts • Fall River, Massachusetts + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 7, 2026, 5:31 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Anthrax AV7909 Boost Evaluation Study

NCT05997264
View directory record Official record
Conditions
Anthrax
Interventions
AV7909 Full Dose (0.5 mL), AV7909 Half Dose (0.25 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL)
Biological
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 65 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
7
States / cities
Hickory, North Carolina • Salisbury, North Carolina • Statesville, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 7, 2026, 5:31 AM EDT
Terminated Phase 1Phase 2 Interventional

A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With Confirmed DDEB or RDEB Diagnosis With One or More Pathogenic Mutations in Exon 73 in the COL7A1 Gene

NCT03605069
View directory record Official record
Conditions
Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica, Dominant
Interventions
QR-313, Placebo
Drug
Lead sponsor
Phoenicis Therapeutics
Industry
Eligibility
4 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
4
States / cities
Palo Alto, California • Aurora, Colorado • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 7, 2026, 5:31 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Effects of Low-Level Laser Stimulation With and Without Fear Extinction Training

NCT02926352
View directory record Official record
Conditions
Phobias, Claustrophobia, Social Phobia
Interventions
Extinction Training, Low-Level Laser Therapy, Sham Low-Level Laser Therapy
Behavioral · Device
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 28, 2022 · Synced Oct 7, 2026, 5:31 AM EDT
Completed Phase 2Phase 3 Interventional Results available

D-cycloserine and Virtual Reality Exposure to Treat Iraq War Veterans With PTSD

NCT00356278
View directory record Official record
Conditions
Stress Disorder, Post Traumatic
Interventions
D-Cycloserine, Alprazolam, Virtual Reality Exposure Therapy, Placebo
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
21 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 8, 2016 · Synced Oct 7, 2026, 5:31 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Metformin in a Non-Diabetic Patient Population

NCT03772964
View directory record Official record
Conditions
Inflammatory Response
Interventions
MetFORMIN Hydrochloride ER, Placebo
Drug
Lead sponsor
Brian Zuckerbraun
Other
Eligibility
55 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 7, 2026, 5:31 AM EDT
Completed Not applicable Interventional

Treatment of Post-Traumatic Stress Disorder (PTSD) and Chronic Pain After Traumatic Orthopedic Injury

NCT00957164
View directory record Official record
Conditions
Chronic Pain, Post-traumatic Stress Disorder
Interventions
Brief Prolonged Exposure Protocol, Chronic Pain Management Treatment, Self-Care
Behavioral
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
18 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Arlington, Texas • Fort Sam Houston, Texas • Lackland Air Force Base, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 7, 2026, 5:31 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Treatment of Sleep Apnea in Patients With Cervical Spinal Cord Injury

NCT02922894
View directory record Official record
Conditions
Sleep Apnea, Spinal Cord Injury
Interventions
Acute episodic hypoxia, Supplemental oxygen, Trazodone, Placebo, Sham
Procedure · Drug
Lead sponsor
John D. Dingell VA Medical Center
Federal
Eligibility
18 Years to 89 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 7, 2026, 5:31 AM EDT
Terminated Phase 2 Interventional

Prospective, Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Symptomatic CD Patients

NCT04243551
View directory record Official record
Conditions
Celiac Disease
Interventions
Latiglutenase, Placebo
Drug · Other
Lead sponsor
Entero Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 7, 2026, 5:31 AM EDT
Completed Not applicable Interventional

Efficacy of Targeted Memory Reactivation for Enhancing Exposure Therapy

NCT04663672
View directory record Official record
Conditions
Claustrophobia, Obsessive-Compulsive Disorder, Arachnophobia
Interventions
Experimental Scent, Control Scent, No-Scent Control, In-Vivo Exposure
Other · Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 65 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 7, 2026, 5:31 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Effect of D-cycloserine on a Short Imagery Rescripting Intervention for Subclinical PTSD

NCT03216356
View directory record Official record
Conditions
PTSD
Interventions
CBT + ImRs, CBT + I.E., D-Cycloserine, Placebo, Study Pill
Behavioral · Drug
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 7, 2026, 5:31 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Transdermal Testosterone Gel for Female Sexual Interest and Arousal Disorder in Peri- and Post Menopause

NCT07408440
View directory record Official record
Conditions
Menopause, Sexual Dysfunction, Libido Disorder, Testosterone Deficiency
Interventions
Transdermal testosterone gel, Transdermal placebo gel
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 7, 2026, 5:31 AM EDT
Terminated Phase 2 Interventional

Study of Latiglutenase in T1D/CD Patients

NCT04839575
View directory record Official record
Conditions
Celiac Disease
Interventions
Latiglutenase, Placebo
Drug
Lead sponsor
Entero Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 7, 2026, 5:31 AM EDT
Recruiting Phase 3 Interventional

A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)

NCT07366034
View directory record Official record
Conditions
Fibrosing Interstitial Lung Disease
Interventions
Nerandomilast, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
2 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 7, 2026, 5:31 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus

NCT03442751
View directory record Official record
Conditions
Progressive Keratoconus
Interventions
Test Article A, Test Article B, Placebo, KXL medical device system
Drug · Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
12 Years to 55 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 7, 2026, 5:31 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy of D-Cycloserine for Enhancing the Effects of CBT for Substance Use

NCT00430573
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
D-cycloserine, Placebo
Drug
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 7, 2026, 5:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Light Therapy for Depression in Adolescent Outpatients

NCT05823090
View directory record Official record
Conditions
Depression, Adolescent - Emotional Problem
Interventions
light box (Carex DayLight Classic Model)
Device
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
12 Years to 18 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 7, 2026, 5:31 AM EDT
Completed Phase 4 Interventional Results available

Combination Treatment for Posttraumatic Stress Disorder (PTSD) After the World Trade Center (WTC) Attack

NCT01130103
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Paroxetine, Prolonged Exposure Therapy
Drug · Behavioral
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2012 · Synced Oct 7, 2026, 5:31 AM EDT
Recruiting Not applicable Interventional

ENhancing Exercise With LIGHT to Improve Functioning in PAD

NCT06399900
View directory record Official record
Conditions
Peripheral Artery Disease, Peripheral Vascular Disease, Aging, Walking, Difficulty
Interventions
Far red light therapy, Sham light therapy, Home-based walking exercise
Device · Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
50 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 7, 2026, 5:31 AM EDT